TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34018624

Group type: EXPERIMENTAL
Intervention: Randomization-based inference for a marginal treatment effect in SWTs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Test statistics derived from individual-level generalized linear models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Data from the XpertMTB/RIF tuberculosis trial
Number of subjects: 0
Study: 35872928

Group type: EXPERIMENTAL
Intervention: Acupotomy and electroacupuncture therapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hot compress, oral medication, and local injection
Number of subjects: 60
Study: 33645201

Group type: COMPARATOR
Intervention: Parathyroid hormone 1‐34 alone (Group A)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Parathyroid hormone 1‐34 plus Zoledronic Acid (ZA) (Group B)
Number of subjects: 96
Study: 32554770

Group type: EXPERIMENTAL
Intervention: Anxiety
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Dyslipidemia
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Migraine
Number of subjects: 959
Study: 35749557

Group type: EXPERIMENTAL
Intervention: Post-abortion phone follow-up by a nurse (trained in person-centered abortion care)
Number of subjects: 371

Group type: COMPARATOR
Intervention: Standard of care (follow-up by service provider call center)
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Post-abortion phone follow-up by a peer counselor (trained in person-centered abortion care)
Number of subjects: 371
Study: 33482681

Group type: EXPERIMENTAL
Intervention: Prophylactic doses of novel direct oral anticoagulants (DOACs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-molecular-weight heparins (LMWHs)
Number of subjects: 0
Study: 32843308

Group type: EXPERIMENTAL
Intervention: Visualized nomogram model based on predictors (maternal age, MsAMH concentration, number of oocytes retrieved)
Number of subjects: 4783

Group type: EXPERIMENTAL
Intervention: Visualized nomogram model validated on independent data from testing set
Number of subjects: 4783
Study: 35340062

Group type: EXPERIMENTAL
Intervention: Denosumab every six months
Number of subjects: 110

Group type: COMPARATOR
Intervention: Risedronate daily
Number of subjects: 110

Group type: COMPARATOR
Intervention: Denosumab and Risedronate
Number of subjects: 110
Study: 33305618

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: Active control program (relaxation)
Number of subjects: 131
Study: 34533487

Group type: EXPERIMENTAL
Intervention: RE only
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: SS
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: MM
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: RE + SS
Number of subjects: 16

Group type: COMPARATOR
Intervention: Rest control (CON)
Number of subjects: 16
Study: 33541274

Group type: EXPERIMENTAL
Intervention: Colistin-based combination therapy
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CPE isolates carrying blaOXA‐232 or blaNDM‐1
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CPE isolates
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: CPKP-ST231
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Siderophores yersiniabactin and aerobactin
Number of subjects: 33
Study: 32077514

Group type: EXPERIMENTAL
Intervention: Acupuncture on specific points
Number of subjects: 49

Group type: COMPARATOR
Intervention: Acupuncture on non-specific points
Number of subjects: 49
Study: 35680197

Group type: EXPERIMENTAL
Intervention: Patients with at least 1 SMuRF
Number of subjects: 2862

Group type: COMPARATOR
Intervention: SMuRF-less patients
Number of subjects: 2862
Study: 32406064

Group type: EXPERIMENTAL
Intervention: N95 respirators
Number of subjects: 20

Group type: COMPARATOR
Intervention: Medical masks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: N95 respirators and medical masks
Number of subjects: 20
Study: 35931948

Group type: EXPERIMENTAL
Intervention: Median nerve block (5 ml of 0.5% lidocaine)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Median nerve block
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (subcutaneous local block)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 36147260

Group type: EXPERIMENTAL
Intervention: Wavefront-Optimized (WFO) PRK
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Wavefront-Guided (WFG) PRK
Number of subjects: 181
Study: 34478235

Group type: EXPERIMENTAL
Intervention: Native vessel PCI
Number of subjects: 3983

Group type: EXPERIMENTAL
Intervention: Venous graft PCI
Number of subjects: 3983

Group type: EXPERIMENTAL
Intervention: Arterial graft PCI
Number of subjects: 3983

Group type: COMPARATOR
Intervention: Overall PCI (native, venous, arterial)
Number of subjects: 3983
Study: 32830092

Group type: EXPERIMENTAL
Intervention: Proton Pump Inhibitors (PPIs)
Number of subjects: 186
Study: 34491291

Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 10
Study: 32866837

Group type: EXPERIMENTAL
Intervention: 10% imidacloprid + 2.5% moxidectin (topical once monthly for 9 months) and doxycycline (10 mg/kg twice daily for 28 days)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Melarsomine dihydrochloride (2.5 mg/kg, two injections 24 hours apart)
Number of subjects: 37
Study: 35101883

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus chemotherapy (in subgroup with PD-L1 expression ≥50%)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (in subgroup with PD-L1 expression ≥50%)
Number of subjects: 98
Study: 33826418

Group type: EXPERIMENTAL
Intervention: BreastFeeding Friend (BFF) app
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control app
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Low quartile users
Number of subjects: 100
Study: 32491239

Group type: EXPERIMENTAL
Intervention: MRI-based radiomics signature
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Combined nomogram integrating independent clinical risk factor α‐fetoprotein (AFP) and radiomics signature
Number of subjects: 293
Study: 35476747

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Health education classes
Number of subjects: 103
Study: 33453563

Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 230
Study: 32819923

Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Sham TEAS (STEAS)
Number of subjects: 146
Study: 36331540

Group type: EXPERIMENTAL
Intervention: Renew mobile mental health app with support from a research staff member
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Renew mobile mental health app without support from a research staff member
Number of subjects: 93

Group type: COMPARATOR
Intervention: Waitlist (delayed use condition)
Number of subjects: 93
Study: 33148722

Group type: EXPERIMENTAL
Intervention: Combined exercise and dietary intervention
Number of subjects: 122

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 122
Study: 35322711

Group type: EXPERIMENTAL
Intervention: High dose vitamin D supplementation (50,000 IU on the first day followed by 10,000 IU/day for 29 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group receiving 1000 IU vitamin D daily and a placebo soft gel
Number of subjects: 0
Study: 32602347

Group type: EXPERIMENTAL
Intervention: Machine learning algorithms based on the mobile screening test system for mild cognitive impairment (mSTS‐MCI)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Korean version of MoCA
Number of subjects: 177
Study: 32242254

Group type: EXPERIMENTAL
Intervention: Regulated dual-task (RDT)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Self-regulated dual-task (SDT)
Number of subjects: 12
Study: 33485328

Group type: EXPERIMENTAL
Intervention: Opioid-free perioperative analgesic pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional opioid-including perioperative medications
Number of subjects: 0
Study: 32620298

Group type: EXPERIMENTAL
Intervention: Gambling involvement measured by six types of gambling behaviours and gambling-related problems in the last year.
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Risk factors identified: male gender, wave 1 gambling, sensation seeking, delinquency, and cyberbullying.
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Protective factors identified: positive relationships with parents and meaningful activities.
Number of subjects: 511
Study: 36915205

Group type: COMPARATOR
Intervention: ENG‐IMPLANT
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: DSG + ENG‐IMPLANT
Number of subjects: 66
Study: 33476534

Group type: EXPERIMENTAL
Intervention: Caffeine citrate injection (5 mg/kg) at 1 hour before ventilator weaning
Number of subjects: 338

Group type: COMPARATOR
Intervention: Routine treatment with caffeine
Number of subjects: 338
Study: 32490650

Group type: EXPERIMENTAL
Intervention: VAH+CAP+SSLF (Group 2)
Number of subjects: 150

Group type: COMPARATOR
Intervention: VAH+CAP (Group 1)
Number of subjects: 150
Study: 35033540

Group type: EXPERIMENTAL
Intervention: Capsulotomy first (Caps-First)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Fragmentation first (Frag-First)
Number of subjects: 70
Study: 34434228

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) training
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard rehabilitation (R)
Number of subjects: 44
Study: 35178149

Group type: EXPERIMENTAL
Intervention: Intervention group (trained using the adapted Pathfinder International Teaching Package on misoprostol use)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Intervention group (after training)
Number of subjects: 68
Study: 32040883

Group type: EXPERIMENTAL
Intervention: Monopolar directional stimulation (DIRECT)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Bipolar stimulation (BIPOLAR = circular anode)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Directional bipolar stimulation (BI‐DIRECT = directional anode)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Bipolar stimulation (BI‐DIRECT)
Number of subjects: 14

Group type: COMPARATOR
Intervention: All stimulation conditions
Number of subjects: 14
Study: 36168097

Group type: EXPERIMENTAL
Intervention: Music intervention
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group (no music)
Number of subjects: 92
Study: 33237533

Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 32314327

Group type: EXPERIMENTAL
Intervention: Liver transplantation (Ltx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional treatment of non-resectable, non-ablatable CLM
Number of subjects: 0
Study: 35430794

Group type: EXPERIMENTAL
Intervention: Carb/fat balance dietary pattern
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Obesogenic dietary pattern
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Dietary changes (energy intake, fat and carbohydrate intakes)
Number of subjects: 242
Study: 33477909

Group type: EXPERIMENTAL
Intervention: Disposable wipes (DWs)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Soap and water (SAW)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Nursing staff satisfaction with DWs
Number of subjects: 138
Study: 35292088

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatment
Number of subjects: 300

Group type: COMPARATOR
Intervention: Waitlist group (control)
Number of subjects: 300
Study: 34391963

Group type: EXPERIMENTAL
Intervention: 18L:6D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 16L:8D and 18L:6D
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: ?18 h photoperiods
Number of subjects: 300
Study: 32146720

Group type: EXPERIMENTAL
Intervention: SRP combined with laser therapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: SRP only (control)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both groups (SRP with and without laser therapy)
Number of subjects: 24
Study: 35351726

Group type: EXPERIMENTAL
Intervention: Let's Grow mHealth intervention
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Usual care plus electronic newsletters
Number of subjects: 1100
Study: 33973840

Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 28749

Group type: COMPARATOR
Intervention: Digital Mammography (DM)
Number of subjects: 28749
Study: 32584384

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (2 mg) monthly for 12 months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravitreal aflibercept injections (2 mg) quarterly for 12 months
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections (2 mg) monthly or quarterly for 12 months
Number of subjects: 32
Study: 34290385

Group type: EXPERIMENTAL
Intervention: Feedback device for ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Feedback device for chest compression
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Feedback device during chest compression
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Feedback device during ventilation
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Feedback device
Number of subjects: 40
Study: 33563325

Group type: EXPERIMENTAL
Intervention: Azithromycin plus standard of care (500 mg qd for 5 days)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 284
Study: 33725432

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine (AZD1222), 5×10^10 viral particles, two doses 21 to 35 days apart
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 2026

Group type: EXPERIMENTAL
Intervention: ChAdOx1 nCoV-19 vaccine (AZD1222)
Number of subjects: 2026
Study: 32048278

Group type: EXPERIMENTAL
Intervention: Standard flow rate facemask
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen with simple facemask
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen
Number of subjects: 80

Group type: COMPARATOR
Intervention: High-flow nasal oxygen (control)
Number of subjects: 80
Study: 35221319

Group type: EXPERIMENTAL
Intervention: Probiotics (Ligilactobacillus salivarius subsp infantis PS11603 and Bifidobacterium longum PS10402)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 32023608

Group type: EXPERIMENTAL
Intervention: Escitalopram (n = 101)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Placebo (n = 86)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Escitalopram (females)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Escitalopram (males)
Number of subjects: 478
Study: 34492623

Group type: COMPARATOR
Intervention: Generational status (traditionalists, baby boomers, generation X, generation Y)
Number of subjects: 3356

Group type: COMPARATOR
Intervention: Generation Y and Generation X
Number of subjects: 3356
Study: 34686204

Group type: EXPERIMENTAL
Intervention: Aclidinium
Number of subjects: 3589
Study: 33397449

Group type: EXPERIMENTAL
Intervention: Conestat alfa (8400 U followed by 4200 U every 8 hours for 72 hours) in addition to standard of care (SOC)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Standard of care (SOC) only
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Conestat alfa (8400 U followed by 4200 U every 8 hours for 72 hours) in addition to SOC
Number of subjects: 120
Study: 32054284

Group type: EXPERIMENTAL
Intervention: Motivational intervention of obesity (IMOAP) with trained nurse and small periodic work groups (G2)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Motivational intervention of obesity (IMOAP) adding the use of a digital platform (iwopi) (G3)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (G1)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (G1) vs Motivational intervention (G2)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (G1) vs Motivational intervention with digital platform (G3)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Motivational intervention (G2) vs Motivational intervention with digital platform (G3)
Number of subjects: 168
Study: 33127746

Group type: EXPERIMENTAL
Intervention: Muc5ac knockout (KCM)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Silencing of MUC5AC in human pancreatic cancer cells
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: MUC5AC-depleted pancreatic cancer cells
Number of subjects: 2
Study: 32493514

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8mg/kg body weight i.v. once, 12 mg/kg for patients <30kg BW, max 800 mg)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo (NaCl) i.v. once
Number of subjects: 200
Study: 35194818

Group type: EXPERIMENTAL
Intervention: 6-week lifestyle medicine program consisting of five lifestyle factors
Number of subjects: 18

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 18
Study: 32142556

Group type: EXPERIMENTAL
Intervention: Rhythmic sensory stimulation (RSS) treatment with different parameters
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rhythmic sensory stimulation (RSS) treatment with different specifications
Number of subjects: 0
Study: 35331538

Group type: EXPERIMENTAL
Intervention: Melatonin (10 mg/day for 24 weeks)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (starch)
Number of subjects: 32
Study: 34441755

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Elvitegravir (EVG/c)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Raltegravir (RAL), Dolutegravir (DTG), Bictegravir (BIC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching from boosted PI or efavirenz to RAL, DTG, or BIC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Switching to Elvitegravir (EVG/c)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Switching trials between INSTIs
Number of subjects: 0
Study: 32121218

Group type: EXPERIMENTAL
Intervention: Low-dose DYM (100 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: High-dose DYM (150 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Low-dose DYM with TCR (100 mg + 50 mg)
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: High-dose DYM with TCR (150 mg + 25 mg)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study: 35848979

Group type: EXPERIMENTAL
Intervention: Acupuncture therapies combined with swallowing training
Number of subjects: 71

Group type: COMPARATOR
Intervention: Swallowing training and rehabilitation consultation (Control)
Number of subjects: 71
Study: 33580200

Group type: EXPERIMENTAL
Intervention: Patients with mutations of BRAF, FBXW7, NRAS, and XPO1 genes
Number of subjects: 600

Group type: COMPARATOR
Intervention: Patients without mutations of BRAF, FBXW7, NRAS, and XPO1 genes
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Patients receiving ≥2 lines of treatment
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Patients dying in winter months
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Patients with 11q deletion
Number of subjects: 600

Group type: COMPARATOR
Intervention: Patients without 11q deletion
Number of subjects: 600
Study: 32702360

Group type: EXPERIMENTAL
Intervention: Acrysof IOL
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Tecnis IOL
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Envista IOL
Number of subjects: 381
Study: 34134818

Group type: EXPERIMENTAL
Intervention: Unified Protocol
Number of subjects: 179

Group type: COMPARATOR
Intervention: Single-diagnosis CBT protocol
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Homework quality
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Homework compliance
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Greater homework quality and compliance
Number of subjects: 179
Study: 32398441

Group type: EXPERIMENTAL
Intervention: 1.8% lidocaine with 1.0 ppm DEX
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 1.8% lidocaine with 2.0 ppm DEX
Number of subjects: 19

Group type: COMPARATOR
Intervention: 1.8% lidocaine with 1:80,000 adrenaline
Number of subjects: 19
Study: 33846100

Group type: EXPERIMENTAL
Intervention: 340B hospitals
Number of subjects: 500

Group type: COMPARATOR
Intervention: non-340B hospitals
Number of subjects: 500
Study: 33273369

Group type: EXPERIMENTAL
Intervention: MUSKARDIA
Number of subjects: 2674

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2674
Study: 36484187

Group type: EXPERIMENTAL
Intervention: Governor vessel moxibustion combined with warming acupuncture
Number of subjects: 64

Group type: COMPARATOR
Intervention: Warming acupuncture
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 64
Study: 34628925

Group type: EXPERIMENTAL
Intervention: Standard haematological care associated with palliative care (PC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard haematological care only
Number of subjects: 0
Study: 36288808

Group type: COMPARATOR
Intervention: Preconception intervention groups (A+B)
Number of subjects: 13500

Group type: COMPARATOR
Intervention: Pregnancy intervention groups
Number of subjects: 13500

Group type: COMPARATOR
Intervention: Preconception and pregnancy interventions
Number of subjects: 13500

Group type: COMPARATOR
Intervention: Pregnancy and early childhood intervention groups
Number of subjects: 13500

Group type: COMPARATOR
Intervention: Preconception, pregnancy, and early childhood interventions
Number of subjects: 13500

Group type: COMPARATOR
Intervention: Preconception intervention groups
Number of subjects: 13500
Study: 34116700

Group type: EXPERIMENTAL
Intervention: Topical rVA576 eye drops, administered twice a day for 8 weeks
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Topical rVA576 eye drops
Number of subjects: 3
Study: 33075444

Group type: EXPERIMENTAL
Intervention: Intervention Group (IG) - received a brochure with supplementary advice, tips, and monthly counselling on food texture introduction.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CG) - received current French recommendations.
Number of subjects: 60